Update: 6 July 2020
Following a review by the UK’s Medicines and Healthcare Regulatory Agency and endorsement from the World Health Organization, the Wellcome-funded COPCOV study on hydroxychloroquine and chloroquine has resumed.
Taken at the right dosage, hydroxychloroquine and chloroquine are safe and effective treatments for malaria, but COVID-19 is a new disease. Only through large-scale clinical studies can we understand how it responds to different treatments.
COPCOV is a prophylaxis study on hydroxychloroquine and chloroquine, which aims to understand whether the drugs can prevent COVID-19 in healthy patients when taken at approved dosage levels, rather than enrolling patients who are already infected with COVID-19. This approach may yield significantly different results.